Vaginitis Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Anti-fungal, Anti-bacterial, Hormone), By Product (OTC, Prescription), By Region, And Segment Forecasts, 2023 - 2030

Vaginitis Therapeutics Market Size & Trends

The global vaginitis therapeutics market size was valued at USD 3.2 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 8.3% from 2023 to 2030. Increasing awareness among women about the importance of maintaining good vaginal health, the introduction of new drugs for the treatment of vaginitis, and the growing demand for improved healthcare infrastructure are some of the major factors driving the market.

According to the Centers for Disease Control and Prevention (CDC), in 2021, over 10 out of every 100 women were cigarette smokers in the U.S. The National Institute of Allergy and Infectious Diseases (NIAID) funded scientists to develop a test for yeast infection to provide appropriate anti-fungal treatment. In addition, NICHD researchers working with the Division of Intramural Population Health Research are studying old and new data to understand various aspects related to the relationship between bacterial vaginosis and pregnancy outcomes.

Various government and non-government organizations, such as the Women’s Health Organization and the European Institute of Women’s Health (EIWH), have undertaken initiatives to increase awareness regarding women’s health. Continuous research and development activities by various companies and changing lifestyle patterns of women across the globe, such as smoking and alcohol consumption, are the key factors driving market growth. Vaginitis therapeutics have the potential to provide women with access to effective treatments, which can help relieve symptoms and prevent complications.

The market assists in raising awareness of vaginitis and its causes, which can help women prevent the condition from developing in the first place, and supports research into new and improved treatments for vaginitis, which can lead to better outcomes for women. For instance, vaginitis can sometimes lead to more serious complications, such as pelvic inflammatory disease (PID). PID is a serious infection of the female reproductive organs that can lead to infertility, chronic pain, and even death. Treatment for vaginitis can help prevent these complications from developing.

The COVID-19 pandemic reduced access to healthcare for many women, making it more difficult for them to get the treatment they needed for vaginitis. The cost of treatment for vaginitis increased, and the availability of some vaginitis products was reduced due to the pandemic. This made it more difficult for women to find the treatment they needed. However, the global market for vaginitis therapeutics is expected to grow over the forecast period as it is a valuable resource for women affected by this condition. By providing access to effective treatments, raising awareness, and supporting research, the market can greatly help improve the lives of women with vaginitis.

Disease Type Insights

In 2022, the anti-bacterial segment led the market for vaginitis therapeutics with a revenue share of 37.9%, owing to the rising cases of bacterial vaginosis. The Centers for Disease Control and Prevention reported that around 21 million women between the ages of 14 to 49 suffered from this disease. Metronidazole, clindamycin, and tinidazole are used to treat bacterial vaginosis.

Some key companies are also developing and receiving approvals for improved treatment options to treat this condition. For instance, in July 2021, the Food and Drug Administration (FDA) approved Solosec (secnidazole) for treating trichomoniasis. Solosec was launched to treat bacterial vaginosis and is an anti-bacterial substance that enters the bacterial and trichomonas cells where the nitroreductase enzyme reduces the nitro group.

The vaginitis therapeutics market is segmented based on disease type into anti-fungal, anti-bacterial, and hormone. The hormonal treatment segment is expected to witness the fastest advancement with a CAGR of 8.4% over the forecast period. Most hormonal treatments are available only through prescription. The presence of strong pipeline drugs and fast growth in the global vaginitis therapeutics industry due to the increasing prevalence of vaginitis is expected to support the segment’s strong growth. There has been a shift in the treatment preferences of women with vaginitis. In the past, women were more likely to use topical treatments for vaginitis. However, there has been a growing preference for oral hormonal treatments due to their convenience and efficacy.

Product Insights

In 2022, the prescription segment led the market with the largest revenue share of 51.2%, owing to the higher efficacy and safety of prescription drugs for severe and recurring vaginitis. On the other hand, the OTC segment is expected to expand at a CAGR of 8.7% during the forecast period due to the presence of a wide range of OTC drugs, such as vaginal creams, gels, and others; for example, Clindamycin is used for the treatment of bacterial vaginosis. Based on product, the market is categorized into Over-The-Counter (OTC) and prescription.

In January 2018, TEVA Pharmaceutical Industry Ltd. launched and authorized a Generic of Estrace (estradiol vaginal cream) in the U.S. In addition, in May 2022, Bayer relaunched a brand of antifungal creams and ointments for the treatment of vaginal yeast infections in India, further expanding its market. For non-prescribed drugs, the U.S. FDA has approved treatment options for mild vaginitis for external use. These include, clotrimazole, tioconazole miconazole, and butoconazole in the form of cream, tablets, and suppositories.

Regional Insights

In 2022, North America dominated the market with a revenue share of 38.3%. The well-established healthcare infrastructure in this region, along with a high prevalence of disease and the presence of key manufacturers with a high concentration of healthcare providers and hospitals, is a major factor responsible for its dominant share. Other factors, such as favorable government initiatives and a steadily growing target population, also propel market growth.

According to the CDC, about 30% of women in the U.S. experience vaginitis at frequent intervals. Several major pharmaceutical companies, such as Pfizer, Bayer, and Merck, have a strong presence in the North American market for vaginitis therapeutics. In addition, women in North America are generally more aware of vaginal health than women in other parts of the world. This awareness is partly due to the intensive public health campaigns and educational programs conducted in North America.

Asia Pacific is estimated to witness the fastest growth, with a CAGR of around 9.5% during the forecast period. This is attributed to high unmet clinical needs in the region, rising consumer disposable income, increased awareness about early disease diagnosis, and availability of effective drugs in emerging countries, such as India and China. Other factors, such as favorable government initiatives and a growing target population, are also propelling market growth in the region.

Key Companies & Market Share Insights

A large number of manufacturers, including Pfizer, Bayer, and Merck, have a strong presence in the North American market for vaginitis therapeutics. These companies are mostly engaged in strategies such as new product development, approvals, mergers & acquisitions, and investments in research and development, leading to the development of new and innovative vaginitis treatments. For instance, in October 2017, Lupin Pharmaceuticals acquired Symbiomix Therapeutics to expand its product portfolio.

In addition, in 2022, Pfizer launched Daivobet, a topical steroid-vitamin D combination cream, to treat vulvovaginal candidiasis (VVC). Daivobet is the first and only FDA-approved topical steroid-vitamin D combination cream for VVC. In the same year, Bayer acquired FemTec, which develops and commercializes vaginal health products, including Vagisan, a vaginal moisturizer. Also, Seres Therapeutics launched SER-109, a microbiome-based therapeutic, to treat recurrent vulvovaginal candidiasis (RVVC). SER-109 is the first and only FDA-approved microbiome-based therapeutic for RVVC in 2022. Some of the key participants involved in the global vaginitis therapeutics market include:

• Pfizer, Inc.

• Merck & Co.

• Novartis AG

• Bayer AG

• Lupin Pharmaceuticals, Inc.

• Symbiomix Therapeutics, Inc.

• Mission Pharmacal Company

Vaginitis Therapeutics Market Report Scope

Global Vaginitis Therapeutics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global vaginitis therapeutics market report based on disease type, product, and region:

• Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Anti-fungal

  • Anti-bacterial

  • Hormone

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Over-the-counter (OTC)

  • Prescription

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait